Home > Haematology > Ibrutinib adds 2.3 years to progression-free survival in mantle-cell lymphoma cases

Ibrutinib adds 2.3 years to progression-free survival in mantle-cell lymphoma cases

Journal
The New England Journal of Medicine
Reuters Health - 03/06/2022 - Ibrutinib extends progression-free survival in older patients with untreated mantle-cell lymphoma (MCL) by 27.7 months, according to a new international study that looked at 523 patients and followed them for a median of more than seven years. When used in combination with bendamustine and rituximab, volunteers who received ibrutinib instead of placebo typically survived 80.6 months without progression of their disease compared with 52.9 months in the control group, a 25% improvement in the incidence of disease progression or death (P=0.01). However, the overall survival rates were similar. Results of the study, known as SHINE, were released at the annual meeting of the American Society of Clinical Oncology and online by the New England Journal of Medicine. The drug is sold under the brand name Imbruvica by Johnson & Johnson, which paid for the study. The once-daily Bruton's tyrosine kinase inhibitor is already approve...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on